Last Price
38.85
Today's Change
+0.15 (0.38%)
Day's Change
38.31 - 39.44
Trading Volume
188,564
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Christopher Peetz Mr. Christopher Peetz
Full Time Employees: 294 294
IPO Date: 2019-07-18 2019-07-18
CIK: 0001759425 0001759425
ISIN: US6047491013 US6047491013
CUSIP: 604749101 604749101
Beta: 1.15 1.15
Last Dividend: 0.00 0.00
Dcf Diff: 27.62 27.62
Dcf: 0.79 0.79
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.